Patents by Inventor Sudha Visvanathan

Sudha Visvanathan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230049147
    Abstract: The present invention provides methods for treating, preventing or ameliorating a fibrotic condition. The methods of the present invention include administering to a patient suffering from a fibrotic condition a therapeutically effective amount an anti-interleukin-36 receptor (anti-IL-36R) antibody.
    Type: Application
    Filed: August 12, 2022
    Publication date: February 16, 2023
    Inventors: Jay FINE, Marc Kaestle, Janine Lamar, David Lamb, Meera Ramanujam, Sudha Visvanathan
  • Publication number: 20220290239
    Abstract: This invention generally relates to biomarkers associated with anti-IL-36R antibody treatment in generalized pustular psoriasis (GPP). The invention also relates to methods of using the biomarkers disclosed.
    Type: Application
    Filed: March 10, 2022
    Publication date: September 15, 2022
    Inventors: Patrick BAUM, Ahmed Karim FARAG, Sudha VISVANATHAN
  • Publication number: 20220089759
    Abstract: The present invention relates to anti-CD40 antibodies and therapeutic methods for using the same for treating and/or preventing autoimmune or inflammatory diseases.
    Type: Application
    Filed: September 17, 2021
    Publication date: March 24, 2022
    Inventors: Fenglei HUANG, Meera RAMANUJAM, Juergen Theodor STEFFGEN, Yasuhiro TSUDA, Sudha VISVANATHAN
  • Publication number: 20220073628
    Abstract: The present invention provides methods for treating, preventing or ameliorating a neutrophilic dermatosis. The methods of the present invention include administering to a patient suffering from a neutrophilic dermatosis a pharmaceutical composition including an anti-interleukin-36 receptor (anit-IL-36R) antibody.
    Type: Application
    Filed: July 15, 2021
    Publication date: March 10, 2022
    Inventors: Jay FINE, Janine LAMAR, Steven John PADULA, Meera RAMANUJAM, Sudha VISVANATHAN
  • Publication number: 20220010022
    Abstract: The present invention provides methods for treating, preventing or ameliorating atopic dermatitis (AtD). In certain embodiments, the invention provides methods to reduce skin infection in a patient with atopic dermatitis. The methods of the present invention include administering to a patient in need thereof a pharmaceutical composition including an anti-interleukin-36 receptor (anit-IL-36R) antibody.
    Type: Application
    Filed: May 17, 2021
    Publication date: January 13, 2022
    Inventors: Mary Ruth FLACK, Jay FINE, Janine LAMAR, Steven John PADULA, Chandrasena Reddy PAMULAPATI, Meera RAMANUJAM, Ralf SIGMUND, Sudha VISVANATHAN, Elizabeta ZOVKO
  • Publication number: 20200376117
    Abstract: This invention generally relates to biomarkers useful in the treatment of IL-23 related diseases, in particular inflammatory diseases such as psoriasis. The invention also relates to methods of using the biomarkers disclosed herein, for example in therapies utilizing IL-23 antagonists.
    Type: Application
    Filed: December 10, 2019
    Publication date: December 3, 2020
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Sudha Visvanathan, Patrick Baum, Oliver Kleiner, Ulrich Kunz
  • Publication number: 20200308271
    Abstract: This invention generally relates to methods for the treatment of IL-23 related diseases, in particular inflammatory diseases, such as psoriasis or psoriatic arthritis, utilizing anti-IL-23A antibodies.
    Type: Application
    Filed: December 21, 2019
    Publication date: October 1, 2020
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Patrick BAUM, Mary Ruth Flack, Annette Bettina Galler, Bojan Lalovic, Kaori Maino, Steven John Padula, Paul Scholl, Koji Sha, Sudha Visvanathan
  • Publication number: 20200299378
    Abstract: This invention generally relates to methods for the treatment of IL-23 related diseases, in particular inflammatory diseases, such as Crohn's Disease, utilizing anti-IL-23A antibodies.
    Type: Application
    Filed: December 13, 2019
    Publication date: September 24, 2020
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Patrick BAUM, Wulf Otto BOECHER, Annette Bettina GALLER, Bojan LALOVIC, Sudha VISVANATHAN
  • Patent number: 10507241
    Abstract: This invention generally relates to biomarkers useful in the treatment of IL-23 related diseases, in particular inflammatory diseases such as psoriasis. The invention also relates to methods of using the biomarkers disclosed herein, for example in therapies utilizing IL-23 antagonists.
    Type: Grant
    Filed: July 23, 2015
    Date of Patent: December 17, 2019
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Sudha Visvanathan, Patrick Baum, Oliver Kleiner, Ulrich Kunz
  • Publication number: 20190359701
    Abstract: This invention generally relates to methods for the treatment of respiratory diseases, such as asthma, utilizing anti-IL-23A antibodies.
    Type: Application
    Filed: March 8, 2019
    Publication date: November 28, 2019
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Kirsten ARNDT-SCHMITZ, Alix BERTON, Michael Chadham NIVENS, Karsten QUAST, Marco SCHLEPUETZ, Sudha VISVANATHAN
  • Publication number: 20180334501
    Abstract: This invention generally relates to methods for the treatment of respiratory diseases, such as asthma, utilizing anti-IL-23A antibodies.
    Type: Application
    Filed: June 27, 2018
    Publication date: November 22, 2018
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Kirsten Arndt-Schmitz, Alix Berton, Michael Chadham Nivens, Karsten Quast, Marco Schlepuetz, Sudha Visvanathan
  • Publication number: 20180105588
    Abstract: This invention generally relates to methods for the treatment of IL-23 related diseases, in particular inflammatory diseases, such as Crohn's Disease, utilizing anti-IL-23A antibodies.
    Type: Application
    Filed: October 11, 2017
    Publication date: April 19, 2018
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Patrick Baum, Wulf Otto Boecher, Annette Bettina Galler, Bojan Lalovic, Sudha Visvanathan
  • Publication number: 20180009887
    Abstract: This invention generally relates to methods for the treatment of respiratory diseases, such as asthma, utilizing anti-IL-23A antibodies.
    Type: Application
    Filed: August 25, 2017
    Publication date: January 11, 2018
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Kirsten Arndt-Schmitz, Alix Berton, Michael Chadham Nivens, Karsten Quast, Marco Schlepuetz, Sudha Visvanathan
  • Publication number: 20170298126
    Abstract: This invention generally relates to methods for the treatment of IL-23 related diseases, in particular inflammatory diseases, such as psoriasis or psoriatic arthritis, utilizing anti-IL-23A antibodies.
    Type: Application
    Filed: April 13, 2017
    Publication date: October 19, 2017
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Patrick BAUM, Mary Ruth FLACK, Annette Bettina GALLER, Bojan LALOVIC, Kaori MAINO, Steven John PADULA, Paul SCHOLL, Koji SHA, Sudha VISVANATHAN
  • Publication number: 20170157246
    Abstract: This invention generally relates to biomarkers useful in the treatment of IL-23 related diseases, in particular inflammatory diseases such as psoriasis. The invention also relates to methods of using the biomarkers disclosed herein, for example in therapies utilizing IL-23 antagonists.
    Type: Application
    Filed: July 23, 2015
    Publication date: June 8, 2017
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Sudha Visvanathan, Patrick BAUM, Oliver KLEINER, Ulrich KUNZ
  • Publication number: 20170081402
    Abstract: This invention generally relates to methods for the treatment of IL-23 related diseases, in particular inflammatory diseases, such as Crohn's Disease, utilizing anti-IL-23A antibodies.
    Type: Application
    Filed: September 15, 2016
    Publication date: March 23, 2017
    Inventors: Wulf Otto BOECHER, Annette Bettina GALLER, Bojan LALOVIC, Steven John PADULA, Paul SCHOLL, Sudha VISVANATHAN
  • Publication number: 20160304602
    Abstract: This invention generally relates to methods for the treatment of respiratory diseases, such as asthma, utilizing anti-IL-23A antibodies.
    Type: Application
    Filed: April 13, 2016
    Publication date: October 20, 2016
    Inventors: Kirsten ARNDT, Alix BERTON, Michael Chadham NIVENS, Karsten QUAST, Marco SCHLEPUETZ, Sudha VISVANATHAN
  • Publication number: 20120178100
    Abstract: The invention provides tools for management of patients diagnosed with psoriatic arthritis, specifically, prior to the initiation of therapy with an anti-TNF? agent. The tools are specific markers and algorithms of predicting response to therapy based on standard clinical primary and secondary endpoints using serum marker concentrations. In one embodiment the baseline levels of VEGF, prostatic acid phosphatase, and adiponectin are used to predict the response at Week 14 after the initiation of therapy. In another embodiment, the change in a serum protein biomarker after 4 weeks of therapy is used such as MDC, lipoprotein a, and beta2-microglobulin.
    Type: Application
    Filed: July 12, 2010
    Publication date: July 12, 2012
    Applicant: CENTOCOR ORTHO BIOTECH INC.
    Inventors: Carrie Wagner, Sudha Visvanathan
  • Publication number: 20110251099
    Abstract: The invention provides tools for management of patients diagnosed with ankylosing spondylitis and prior to the initiation of therapy with an anti-TNFalpha agent. The tools are specific markers and algorithms of predicting response to therapy based on standard clinical primary and secondary end-points using serum marker concentrations. In one embodiment the baseline level of leptin or osteocalcin is used to predict the response at Week 14 after the initiation of therapy. In another embodiment, the change in a serum protein biomarker after 4 weeks of therapy is used such as complement component 3.
    Type: Application
    Filed: December 9, 2009
    Publication date: October 13, 2011
    Inventors: Sudha Visvanathan, Carrie Wagner